News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prima Biomed (PRR.AX) Shareholders' Briefing Webcast & Dial In Details



6/13/2012 8:45:14 AM

SYDNEY, AUSTRALIA--(Marketwire - June 12, 2012) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) confirms the webcast and dial in details for the shareholder briefing to be held on Friday 15th June 2012, at 9:30am (Sydney time).

Webcast link

Shareholders who are unable to attend the meeting and wish to view the proceedings on the Webcast should use the following link:

http://events.knowledgevision.com/staging/The_Prima_Biomed_Shareholder_Briefing.html

Shareholders who would also like to ask a question at the meeting are requested to dial in on one of the following numbers:

Dial in Numbers:

Australia Toll Free 1 800 131 617 Australia Alternate Toll Free 1 800 838 758 Canada/USA 1 855 624 0077 China Wide 10 800 140 1776 France 0800 913 734 Germany 0800 183 0918 Hong Kong 0800 968 273 India 0008 0010 08070 Indonesia 001 803 321 8057 Ireland 1800 948 607 Japan 006633 868000 Malaysia 1800 816 441 New Zealand 0800 452 795 Singapore 800 101 2702 South Africa 0800 984 013 Switzerland 0800 802 498 Taiwan 0080 112 7377 UAE 8000 3570 2706 United Kingdom 0800 051 1453

About Prima BioMed

Prima BioMed is a global biotechnology company headquartered in Australia. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer.


For further information please contact:

Mr James Moses
Investor and Media Relations
Mandate Corporate
Ph: +61 (0) 420 991 574
E: Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES